Clinical Trial Search

Primary: Percentage of Participants With CDI Recurrence — 14.9; 15.7; 25.7 Percentage of participants — p=<0.0001

Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.10; -0.85 percentage of hemoglobin — p=<0.0001

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.42; -0.83; -0.92 percentage of hemoglobin — p=<0.0001

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…

Primary: Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio…

Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 — 74.6; 72.4 percentage of participants

Primary: Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16 — 80.91; 83.06 percent change

Primary: Percentage of Patients With Serum PSA Levels ≤4.0 ng/mL — 100; 98.4 Percentage of patients

Primary: Adverse Events (AEs)(Serious and Non-serious) — 920; 19; 901 Events

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 80 percentage of participants

Primary: Numbers of Subjects With Any and Grade 3 Solicited Local Symptoms — 105; 55; 40; 1 Participants

Primary: Disease-free Survival (DFS) — 5.8; 6.1; 6.6 years — p=0.80

Primary: Progression Free Survival (PFS) — 18.3; 3.6 months

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — -0.19; -0.73; -0.85 percentage of hemoglobin — p=<0.0001